CD19CD22 CAR-T Therapy in Patients With High-Risk B Acute Lymphoblastic Leukemia (B-ALL).
Clinical trial for the safety and efficacy of induction chemotherapy with VA regime and bridging CD19CD22 CAR-T therapy in adult patients with newly diagnosed high-risk and Ph- B-ALL
B Acute Lymphoblastic Leukemia|Ph-Negative ALL|High Risk Acute Lymphoblastic Leukemia
DRUG: Azacitidine Injection|DRUG: Venetoclax|DRUG: CD19CD22 CAR-T
Complete Remission Rate, MRD Negative Remission Rate after CD19CD22 cell therapy, The cycle of CD19CD22 cell therapy is day 2-4; Effect evaluation was day 21 after CD19CD22 cells infusion
Complete Remission Rate of VA regime, Complete Remission Rate after VA regime, The cycle of VA regime is day 21; Effect evaluation was day 7 after VA regime|Complete Molecular Remission Rate, Complete Molecular Remission Rate after CD19CD22 CAR-T cell therapy, The cycle of CD19CD22 cell therapy is day 2-4; Effect evaluation was day 21 after CD19CD22 cells infusion|Overall survival (OS), From the first infusion of CD19CD22 cells to death or the last visit, The cycle of CD19CD22 cell therapy is day 2-4; Effect evaluation was 2 years after CD19CD22 CAR-T cells infusion|Leukemia-free survival (LFS), Up to 2 years after CD19CD22 CAR-T cells infusion, The cycle of CD19CD22 cell therapy is day 2-4; Effect evaluation was 2 years after CD19CD22 CAR-T cells infusion
To evaluate the safety and efficacy of induction chemotherapy with VA regime and bridging CD19CD22 CAR-T therapy in Adult patients with newly diagnosed high-risk and Ph- B-ALL in this prospective, single arm study.